Understanding Tysabri and PML Diagnosis: Key Facts for Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Exposure Concerns

If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding how this rare brain infection is diagnosed is critical. The medical community has long emphasized the importance of early detection through regular monitoring, which forms the basis of current guidelines. This page explains the diagnostic process for PML in Tysabri patients, including key tests and what to expect.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically addressing this risk. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. The infection is caused by the JC virus and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical symptoms can vary widely but often include progressive neurological deficits such as weakness, gait disturbance, memory impairment, and cognitive decline. In FDA adverse event reports for Tysabri, common neurological symptoms include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms can overlap with multiple sclerosis itself, any new or worsening neurological signs should prompt immediate evaluation for PML. Diagnosis typically involves brain MRI and cerebrospinal fluid analysis for JC virus DNA.

Mechanistic Pathways and Risk Factors for PML

The link between Tysabri and PML is mechanistically understood. By blocking lymphocyte trafficking to the brain, Tysabri reduces the immune system's ability to control JC virus reactivation. Three specific risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA has mandated a boxed warning for Tysabri that clearly states the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies risk factors including anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude and timing of PML risk, particularly regarding the cumulative risk over extended treatment periods.

Legal Considerations for Affected Patients

For patients who develop PML after Tysabri treatment, legal considerations may include whether the manufacturer provided sufficient warnings about PML risk, whether risk factors were properly communicated, and whether monitoring recommendations were followed. The boxed warning and restricted distribution program indicate that the FDA and manufacturer recognized the serious nature of this risk. However, affected individuals may need to evaluate whether they received adequate information about the specific risk factors—such as anti-JCV antibody status and treatment duration—and whether their healthcare providers appropriately monitored for PML symptoms. Legal counsel can help assess whether a patient's PML diagnosis was foreseeable based on known risk factors and whether any failure to warn or monitor contributed to the outcome. The onset of PML can occur at various points during Tysabri treatment. In clinical trials, one case occurred after eight doses in a Crohn's disease patient, while two multiple sclerosis patients developed PML after a median treatment duration of 120 weeks (approximately 2.3 years) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variable latency means that patients may develop PML after months or years of therapy, and symptoms may initially be mistaken for multiple sclerosis relapse. Prompt recognition and withholding of Tysabri are critical, as the boxed warning instructs healthcare professionals to withhold dosing immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is its link to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML in Tysabri patients?

Symptoms include progressive neurological deficits such as weakness, gait disturbance, memory impairment, cognitive decline, fatigue, headache, and balance disorder. These can overlap with multiple sclerosis symptoms, so any new or worsening signs should prompt immediate evaluation (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri patients?

Diagnosis typically involves brain MRI and cerebrospinal fluid analysis for JC virus DNA. Healthcare professionals are instructed to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for patients who developed PML after Tysabri?

Patients may consider legal action if they believe the manufacturer failed to provide adequate warnings about PML risk or if healthcare providers did not properly monitor for symptoms. Legal counsel can assess whether the PML diagnosis was foreseeable and whether any failure to warn or monitor contributed to the outcome.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.